JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on September 19, 2006; DOI: 10.1124/jpet.106.111724


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.111724v1
319/3/1162    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Du, L.
Right arrow Articles by Keeney, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Du, L.
Right arrow Articles by Keeney, D. S.


Received for publication August 8, 2006.
Revised September 14, 2006.
Accepted for publication September 15, 2006.

Differentiation-specific factors modulate epidermal CYP1-4 gene expression in human skin in response to retinoic acid and classical aryl hydrocarbon receptor ligands

Liping Du 1, Mark M Neis 2, Patricia A Ladd 1, Diane S. Keeney 1*

1 Vanderbilt University 2 University Hospital of the RWTH

* Address correspondence to: E-mail: diane.keeney{at}vanderbilt.edu

Abstract

Human epidermal keratinocytes express subsets of cytochromes P450 (CYP gene products) that are strongly up-regulated, not regulated, or down-regulated by differentiation-specific factors. We investigated how drug exposure affects epidermal expression of CYP1-4 genes, which encode many drug metabolizing CYPs. Real-time PCR assays measured CYP1-4 mRNA levels in epidermal keratinocytes differentiated in vitro in the presence of drug or vehicle for six days. We confirmed the spinous phenotype at Day 6 by changes in cellular morphology and up-regulation of cytokeratin 10 and transglutaminase (TGM) 1 mRNA in the differentiating keratinocytes. Effects of drug exposure depended on the influence of differentiation-specific factors in controlling epidermal CYP1-4 expression. CYP2C18, 2C19, 2C9, 2W1, 3A4, and 4B1 are up-regulated by cellular differentiation; mRNA levels for these CYP genes were inhibited in differentiating keratinocytes exposed to retinoic acid and aryl hydrocarbon receptor (AhR) ligands. These same drugs effected ≤2-fold change or even augmented mRNA levels for CYP genes that are not regulated by differentiation (CYP2S1, 2J2, 1B1, 1A1, 1A2, 2E1, 2D6) and for CYP2U1, which is expressed at highest levels in undifferentiated keratinocytes. The clinically relevant drugs miconazole, dexamethasone, rifampicin, and dapsone had little effect on CYP1-4 mRNA levels under assay conditions. The AhR ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin also up-regulated keratinocyte TGM1 mRNA in a concentration- and time-dependent manner. This effect was blocked by the AhR antagonist resveratrol. These findings implicate AhR-dependent up-regulation of TGM1 mRNA in differentiating keratinocytes as one mechanism contributing towards chloracne in humans exposed to toxic levels of dioxin.


Key words: CYP, cytochrome P450, drug metabolism, epithelial cell, keratinocyte, skin


This article has been cited by other articles:


Home page
FASEB J.Home page
A. Kalsotra, L. Du, Y. Wang, P. A. Ladd, Y. Kikuta, M. Duvic, A. S. Boyd, D. S. Keeney, and H. W. Strobel
Inflammation resolved by retinoid X receptor-mediated inactivation of leukotriene signaling pathways
FASEB J, February 1, 2008; 22(2): 538 - 547.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.